The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Eric S. Winer
Consulting or Advisory Role - Jazz Pharmaceuticals; Novartis; Pfizer; Takeda
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Immunogen; Incyte; Novartis; Pfizer; takeda
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); glycomimetics (Inst); Novartis (Inst)
 
Stefano R. Tarantolo
No Relationships to Disclose
 
David Andrew Sallman
Consulting or Advisory Role - Abbvie; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Intellia Therapeutics; Janssen; Kite, a Gilead company; Magenta Therapeutics; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Incyte; SERVIER
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals
 
James Dugan
No Relationships to Disclose
 
Stefanie Groepper
No Relationships to Disclose
 
Aristoteles Giagounidis
Stock and Other Ownership Interests - Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
 
Katharina S. Gotze
No Relationships to Disclose
 
Klaus Metzeler
No Relationships to Disclose
 
Chia-Cheng Li
No Relationships to Disclose
 
Li Zhou
Employment - Crinetics Pharmaceuticals (I); Syros Pharmaceuticals
Stock and Other Ownership Interests - Black Diamond Therapeutics; Incyte; Replimune; Seagen; Syros Pharmaceuticals
 
Elizabeth Martinez
No Relationships to Disclose
 
Maureen E Lane
No Relationships to Disclose
 
Reinhard W. Von Roemeling
Employment - Curis
Leadership - Curis
 
Matthias Bohme
No Relationships to Disclose
 
Anne Sophie Kubasch
No Relationships to Disclose
 
Amit K. Verma
No Relationships to Disclose
 
Uwe Platzbecker
Honoraria - Celgene/Jazz
Consulting or Advisory Role - Celgene/Jazz
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019)
Travel, Accommodations, Expenses - Celgene